Hagens Berman probes Ionis after 23% stock plunge on failed Phase 3 trial

The law firm said it is examining whether Ionis was sufficiently transparent about eplontersen trial data and design after the July 9 setback erased more than $3.3 billion in market value.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.